Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis
dc.contributor.author | Deyab, Gia | |
dc.contributor.author | Hokstad, Ingrid | |
dc.contributor.author | Whist, Jon Elling | |
dc.contributor.author | Småstuen, Milada C | |
dc.contributor.author | Agewall, Stefan | |
dc.contributor.author | Lyberg, Torstein | |
dc.contributor.author | Ronda, Nicoletta | |
dc.contributor.author | Mikkelsen, Knut | |
dc.contributor.author | Hjeltnes, Gunnbjørg | |
dc.contributor.author | Hollan, Ivana | |
dc.date.accessioned | 2018-03-06T09:09:53Z | |
dc.date.accessioned | 2018-06-18T11:59:14Z | |
dc.date.available | 2018-03-06T09:09:53Z | |
dc.date.available | 2018-06-18T11:59:14Z | |
dc.date.issued | 2017-10-17 | |
dc.identifier.citation | Deyab G, Hokstad I, Whist Je, Småstuen MC, Agewall S, Lyberg T, Ronda N, Mikkelsen K, Hjeltnes G, Hollan I. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Research & Therapy. 2017;19:232:1-10 | en |
dc.identifier.issn | 1478-6362 | |
dc.identifier.issn | 1478-6362 | |
dc.identifier.uri | https://hdl.handle.net/10642/5964 | |
dc.description.abstract | Background: Inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), leads to increased cardiovascular disease occurrence probably due to atherosclerosis. One of the first stages in atherogenesis is endothelial dysfunction (ED). Therefore, we aimed to compare endothelial function (EF) in patients with IA, and to examine the effects of methotrexate (MTX) monotherapy and antitumor necrosis factor (anti-TNF) treatment with or without MTX comedication (anti-TNF±MTX) on EF. Methods: From the PSARA observational study, all patients with RA (n=64), PsA (n=29), and AS (n=20) were evaluated for EF. In patients with ED at baseline (n=40), we evaluated changes in the Reactive Hyperemic Index (RHI) after 6 weeks and 6 months of antirheumatic therapy. Results: In IA patients with ED, RHI significantly improved after 6 weeks (p<0.001) and 6 months (p<0.001) of treatment, independent of changes in disease activity parameters. After 6 months, RHI had improved more in the MTX group than in the anti-TNF±MTX group, and the difference remained statistically significant after adjustments for potential confounders. Among patients with active RA, AS, and PsA, those with AS appeared to have the worst endothelial function, although they were the youngest. Conclusion: Treatment with MTX and anti-TNF±MTX was associated with a relatively fast improvement of EF in IA patients with ED, independent of change in disease activity. Therefore, modes of action other than the antiinflammatory effect may contribute to the EF improvement. After 6 months, the EF improvement was more pronounced in the MTX group than in the anti-TNF±MTX group. | en |
dc.language.iso | en | en |
dc.publisher | BioMed Central | en |
dc.relation.ispartofseries | Arthritis Research & Therapy;Volume 19: 232 | |
dc.rights | © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Methotrexate | en |
dc.subject | Inflammatory arthritis | en |
dc.subject | Anti-tumor necrosis factors | en |
dc.subject | Rheumatic arthritis | en |
dc.title | Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2018-03-06T09:09:53Z | |
dc.description.version | publishedVersion | en |
dc.identifier.doi | https://doi.org/10.1186/s13075-017-1439-1 | |
dc.identifier.cristin | 1521997 | |
dc.source.journal | Arthritis Research & Therapy |
Tilhørende fil(er)
Denne innførselen finnes i følgende samling(er)
-
HV - Institutt for sykepleie og helsefremmende arbeid [1410]
HV - Department of Nursing and Health Promotion
Med mindre annet er angitt, så er denne innførselen lisensiert som © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.